JPWO2020079448A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020079448A5 JPWO2020079448A5 JP2021546487A JP2021546487A JPWO2020079448A5 JP WO2020079448 A5 JPWO2020079448 A5 JP WO2020079448A5 JP 2021546487 A JP2021546487 A JP 2021546487A JP 2021546487 A JP2021546487 A JP 2021546487A JP WO2020079448 A5 JPWO2020079448 A5 JP WO2020079448A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- nucleic acid
- sequence
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 description 81
- 201000011510 cancer Diseases 0.000 description 52
- 210000004027 cells Anatomy 0.000 description 49
- 150000007523 nucleic acids Chemical class 0.000 description 43
- 108020004707 nucleic acids Proteins 0.000 description 42
- 230000002163 immunogen Effects 0.000 description 35
- 239000000203 mixture Substances 0.000 description 35
- 230000027455 binding Effects 0.000 description 23
- 239000000427 antigen Substances 0.000 description 18
- 102000038129 antigens Human genes 0.000 description 18
- 108091007172 antigens Proteins 0.000 description 18
- 206010025650 Malignant melanoma Diseases 0.000 description 16
- 201000001441 melanoma Diseases 0.000 description 14
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 description 13
- 230000000875 corresponding Effects 0.000 description 12
- 210000001808 Exosomes Anatomy 0.000 description 10
- 230000001472 cytotoxic Effects 0.000 description 10
- 231100000433 cytotoxic Toxicity 0.000 description 10
- 230000002265 prevention Effects 0.000 description 7
- 210000001744 T-Lymphocytes Anatomy 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 230000028993 immune response Effects 0.000 description 5
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 201000003708 skin melanoma Diseases 0.000 description 4
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000003308 immunostimulating Effects 0.000 description 3
- 210000000265 Leukocytes Anatomy 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 210000001745 Uvea Anatomy 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 201000005969 uveal melanoma Diseases 0.000 description 2
- 229960005486 vaccines Drugs 0.000 description 2
- 230000003612 virological Effects 0.000 description 2
- 241000432074 Adeno-associated virus Species 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000002416 Cutaneous Malignant Melanoma Diseases 0.000 description 1
- 210000004443 Dendritic Cells Anatomy 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229960001438 IMMUNOSTIMULANTS Drugs 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 229920001850 Nucleic acid sequence Polymers 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- 108050006987 Poxvirus Proteins 0.000 description 1
- 210000004927 Skin cells Anatomy 0.000 description 1
- 108091008153 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100012087 TLR4 Human genes 0.000 description 1
- 101700022711 TLR4 Proteins 0.000 description 1
- 102100006355 TLR7 Human genes 0.000 description 1
- 101700075266 TLR7 Proteins 0.000 description 1
- 102100006354 TLR8 Human genes 0.000 description 1
- 101700071772 TLR8 Proteins 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000000890 antigenic Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 230000003344 immunostimulant Effects 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 102000005614 monoclonal antibodies Human genes 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022173369A JP2023017853A (ja) | 2018-10-19 | 2022-10-28 | 新規な癌抗原及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18201634 | 2018-10-19 | ||
| EP18201634.5 | 2018-10-19 | ||
| PCT/GB2019/052980 WO2020079448A1 (en) | 2018-10-19 | 2019-10-18 | Novel cancer antigens and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022173369A Division JP2023017853A (ja) | 2018-10-19 | 2022-10-28 | 新規な癌抗原及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022514116A JP2022514116A (ja) | 2022-02-09 |
| JPWO2020079448A5 true JPWO2020079448A5 (xx) | 2022-11-10 |
Family
ID=64183836
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546487A Pending JP2022514116A (ja) | 2018-10-19 | 2019-10-18 | 新規な癌抗原及び方法 |
| JP2022173369A Pending JP2023017853A (ja) | 2018-10-19 | 2022-10-28 | 新規な癌抗原及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022173369A Pending JP2023017853A (ja) | 2018-10-19 | 2022-10-28 | 新規な癌抗原及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210353729A1 (xx) |
| EP (1) | EP3866827A1 (xx) |
| JP (2) | JP2022514116A (xx) |
| KR (1) | KR20210080372A (xx) |
| CN (1) | CN112867501A (xx) |
| AU (1) | AU2019360427A1 (xx) |
| BR (1) | BR112021006941A2 (xx) |
| CA (1) | CA3112427A1 (xx) |
| EA (1) | EA202191081A1 (xx) |
| IL (1) | IL282308A (xx) |
| MX (1) | MX2021004453A (xx) |
| WO (1) | WO2020079448A1 (xx) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3179694A1 (en) * | 2020-04-17 | 2021-10-21 | The Francis Crick Institute Limited | Fusion proteins of ctl antigens for treating melanoma |
| EP4136096A1 (en) * | 2020-04-17 | 2023-02-22 | The Francis Crick Institute Limited | Antigen pool |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0871747A1 (en) | 1996-01-02 | 1998-10-21 | Chiron Viagene, Inc. | Immunostimulation mediated by gene-modified dendritic cells |
| US6770456B1 (en) | 1998-07-29 | 2004-08-03 | Ludwig Institute For Cancer Research | Endogenous retrovirus tumor associated nucleic acids and antigens |
| WO2001064835A2 (en) * | 2000-02-28 | 2001-09-07 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| EP1586330A1 (en) | 2004-04-16 | 2005-10-19 | Georg-August-Universität Göttingen | Vaccination against malignant melanoma |
| EP2402447A1 (en) | 2005-03-30 | 2012-01-04 | Viroxis | Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment |
| AT502292B1 (de) | 2005-05-11 | 2010-04-15 | Avir Green Hills Biotechnology | Melanomdiagnose |
| US8921050B2 (en) * | 2006-03-17 | 2014-12-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of diagnosing renal cell carcinoma |
| WO2007137279A2 (en) | 2006-05-22 | 2007-11-29 | Board Of Regents, The University Of Texas System | Herv-k antigens, antibodies, and methods |
-
2019
- 2019-10-18 EP EP19790765.2A patent/EP3866827A1/en active Pending
- 2019-10-18 MX MX2021004453A patent/MX2021004453A/es unknown
- 2019-10-18 JP JP2021546487A patent/JP2022514116A/ja active Pending
- 2019-10-18 CN CN201980068630.3A patent/CN112867501A/zh active Pending
- 2019-10-18 WO PCT/GB2019/052980 patent/WO2020079448A1/en unknown
- 2019-10-18 AU AU2019360427A patent/AU2019360427A1/en active Pending
- 2019-10-18 EA EA202191081A patent/EA202191081A1/ru unknown
- 2019-10-18 CA CA3112427A patent/CA3112427A1/en active Pending
- 2019-10-18 KR KR1020217010920A patent/KR20210080372A/ko active Search and Examination
- 2019-10-18 BR BR112021006941-0A patent/BR112021006941A2/pt unknown
-
2021
- 2021-04-13 IL IL282308A patent/IL282308A/en unknown
- 2021-04-16 US US17/232,597 patent/US20210353729A1/en active Pending
-
2022
- 2022-10-28 JP JP2022173369A patent/JP2023017853A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Cancer vaccines as promising immuno-therapeutics: platforms and current progress | |
| Arab et al. | HER2-positive breast cancer immunotherapy: a focus on vaccine development | |
| Molino et al. | Viral-mimicking protein nanoparticle vaccine for eliciting anti-tumor responses | |
| Wong et al. | Advances in therapeutic cancer vaccines | |
| JP2001524928A (ja) | クロスプライミング免疫による天然抗原に特異性を有するｃｔｌの誘導 | |
| KR20120098919A (ko) | 암의 치료제 | |
| US12059460B2 (en) | Immunogenic compounds for cancer therapy | |
| AU2022200872B2 (en) | Immunogenic compounds for cancer therapy | |
| AU2015233542A1 (en) | A medicament for use in a method of inducing or extending a cellular cytotoxic immune response | |
| JPWO2020079448A5 (xx) | ||
| Boliukh et al. | Immunological aspects of heat shock protein functions and their significance in the development of cancer vaccines | |
| WO2004012685A2 (en) | Shed antigen vaccine with dendritic cells adjuvant | |
| JP2018528960A5 (xx) | ||
| JPWO2021005339A5 (xx) | ||
| JPWO2021005338A5 (xx) | ||
| JPWO2020260897A5 (xx) | ||
| US20110104101A1 (en) | Immunotherapy for Unresectable Pancreatic Cancer | |
| Zhou | Therapeutic Vaccines in Breast Cancer | |
| JPWO2020260898A5 (xx) | ||
| STROMAL | 289 PGV-001: A PHASE 1 TRIAL OF A PERSONALIZED NEOANTIGEN PEPTIDE VACCINE FOR THE TREATMENT OF MALIGNANCIES IN THE ADJUVANT SETTING | |
| CN117813108A (zh) | 基于肽的新抗原疫苗的多组分化学组合物 | |
| Dranoff | Advances in Therapeutic Cancer Vaccines | |
| AU7909700A (en) | New lymphocytes, a process for preparing the same and their use in therapeutics | |
| Yang et al. | Active immunotherapy in glioma: Focus on cell-based approaches | |
| Foon et al. | T lymphocytes |